Annual Cash & Cash Equivalents
$119.89 M
+$59.98 M+100.09%
December 31, 2023
Summary
- As of February 7, 2025, IKNA annual cash & cash equivalents is $119.89 million, with the most recent change of +$59.98 million (+100.09%) on December 31, 2023.
- During the last 3 years, IKNA annual cash & cash equivalents has fallen by -$42.60 million (-26.21%).
- IKNA annual cash & cash equivalents is now -48.37% below its all-time high of $232.22 million, reached on December 31, 2021.
Performance
IKNA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$45.19 M
+$922.00 K+2.08%
September 30, 2024
Summary
- As of February 7, 2025, IKNA quarterly cash and cash equivalents is $45.19 million, with the most recent change of +$922.00 thousand (+2.08%) on September 30, 2024.
- Over the past year, IKNA quarterly cash and cash equivalents has dropped by -$76.09 million (-62.74%).
- IKNA quarterly cash and cash equivalents is now -83.92% below its all-time high of $281.01 million, reached on March 31, 2021.
Performance
IKNA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
IKNA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.1% | -62.7% |
| 3 y3 years | -26.2% | -36.2% |
| 5 y5 years | +46.1% | -36.2% |
IKNA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -48.4% | +100.1% | -80.5% | +54.1% |
| 5 y | 5-year | -48.4% | +100.1% | -83.9% | +54.1% |
| alltime | all time | -48.4% | +100.1% | -83.9% | +54.1% |
Ikena Oncology Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $45.19 M(+2.1%) |
| Jun 2024 | - | $44.27 M(-16.2%) |
| Mar 2024 | - | $52.85 M(-55.9%) |
| Dec 2023 | $119.89 M(+100.1%) | $119.89 M(-1.1%) |
| Sep 2023 | - | $121.28 M(+71.1%) |
| Jun 2023 | - | $70.87 M(+141.6%) |
| Mar 2023 | - | $29.33 M(-51.1%) |
| Dec 2022 | $59.92 M | $59.92 M(-10.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $67.07 M(+38.3%) |
| Jun 2022 | - | $48.49 M(+3.4%) |
| Mar 2022 | - | $46.88 M(-79.8%) |
| Dec 2021 | $232.22 M(+42.9%) | $232.22 M(-5.6%) |
| Sep 2021 | - | $245.90 M(-6.9%) |
| Jun 2021 | - | $264.00 M(-6.1%) |
| Mar 2021 | - | $281.01 M(+72.9%) |
| Dec 2020 | $162.49 M(+98.0%) | $162.49 M |
| Dec 2019 | $82.08 M | - |
FAQ
- What is Ikena Oncology annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ikena Oncology?
- What is Ikena Oncology annual cash & cash equivalents year-on-year change?
- What is Ikena Oncology quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Ikena Oncology?
- What is Ikena Oncology quarterly cash and cash equivalents year-on-year change?
What is Ikena Oncology annual cash & cash equivalents?
The current annual cash & cash equivalents of IKNA is $119.89 M
What is the all time high annual cash & cash equivalents for Ikena Oncology?
Ikena Oncology all-time high annual cash & cash equivalents is $232.22 M
What is Ikena Oncology annual cash & cash equivalents year-on-year change?
Over the past year, IKNA annual cash & cash equivalents has changed by +$59.98 M (+100.09%)
What is Ikena Oncology quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IKNA is $45.19 M
What is the all time high quarterly cash and cash equivalents for Ikena Oncology?
Ikena Oncology all-time high quarterly cash and cash equivalents is $281.01 M
What is Ikena Oncology quarterly cash and cash equivalents year-on-year change?
Over the past year, IKNA quarterly cash and cash equivalents has changed by -$76.09 M (-62.74%)